bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure S2 from Radiation-Induced Amplification of TGFB1-Induced Mesenchymal Stem Cell–Mediated Sodium Iodide Symporter (NIS) Gene 131I Therapy
Authors: Schug Christina , Kitzberger Carolin , Sievert Wolfgang , Spellerberg Rebekka , Tutter Mariella , Schmohl Kathrin A. , Eberlein Bernadette , Biedermann Tilo , Steiger Katja , Zach Christian , Schwaiger Markus , Multhoff Gabriele , Wagner Ernst , Nelson Peter J. , Spitzweg Christine
Published: April 2023

Supplementary Figure S2. Immunofluorescence staining of proliferating cells (Ki67) and blood vessels (CD31). Immunofluorescence analysis for Ki67 (green) and CD31 (red) showed no difference in proliferation as well as blood vessel density in resected tumors of mice treated with radiation and SMAD-NIS MSC followed by 131I treatment as compared to therapy mice receiving CMV-NIS-MSCs or irradiated tumors of mice injected with SMAD-NIS MSCs and NaCl or non-irradiated tumors receiving NaCl only (A-C). Slides of tumors were counterstained with Hoechst nuclear stain and one representative image is shown each (20Ã- magnification) (A).
Supplementary Data File S2 from Metformin Abrogates Age-Associated Ovarian Fibrosis
Authors: McCloskey Curtis W. , Cook David P. , Kelly Brendan S. , Azzi Feryel , Allen Christian H. , Forsyth Amanda , Upham Jeremy , Rayner Katey J. , Gray Douglas A. , Boyd Robert W. , Murugkar Sangeeta , Lo Bryan , Trudel Dominique , Senterman Mary K. , Vanderhyden Barbara C.
Published: April 2023

Grouped Nanostring data with gliptin samples omitted.
Figure S4 from Metformin Abrogates Age-Associated Ovarian Fibrosis
Authors: McCloskey Curtis W. , Cook David P. , Kelly Brendan S. , Azzi Feryel , Allen Christian H. , Forsyth Amanda , Upham Jeremy , Rayner Katey J. , Gray Douglas A. , Boyd Robert W. , Murugkar Sangeeta , Lo Bryan , Trudel Dominique , Senterman Mary K. , Vanderhyden Barbara C.
Published: April 2023

Non-significant alteration in the immune and stromal landscape of the ovarian cortex with metformin use.
Table S2 from The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma
Authors: Buhl Juliane L. , Selt Florian , Hielscher Thomas , Guiho Romain , Ecker Jonas , Sahm Felix , Ridinger Johannes , Riehl Dennis , Usta Diren , Ismer Britta , Sommerkamp Alexander C. , Martinez-Barbera J.P. , Wefers Annika K. , Remke Marc , Picard Daniel , Pusch Stefan , Gronych Jan , Oehme Ina , van Tilburg Cornelis M. , Kool Marcel , Kuhn Daniela , Capper David , von Deimling Andreas , Schuhmann Martin U. , Herold-Mende Christel , Korshunov Andrey , Brummer Tilman , Pfister Stefan M. , Jones David T.W. , Witt Olaf , Milde Till
Published: April 2023

Clinical annotations of the multiplex assay PA cohort and normal brain
Figure S2 from Metformin Abrogates Age-Associated Ovarian Fibrosis
Authors: McCloskey Curtis W. , Cook David P. , Kelly Brendan S. , Azzi Feryel , Allen Christian H. , Forsyth Amanda , Upham Jeremy , Rayner Katey J. , Gray Douglas A. , Boyd Robert W. , Murugkar Sangeeta , Lo Bryan , Trudel Dominique , Senterman Mary K. , Vanderhyden Barbara C.
Published: April 2023

Automated microdissection and immunohistochemical analysis of the human ovarian cortex.
Figure S1 from Metformin Abrogates Age-Associated Ovarian Fibrosis
Authors: McCloskey Curtis W. , Cook David P. , Kelly Brendan S. , Azzi Feryel , Allen Christian H. , Forsyth Amanda , Upham Jeremy , Rayner Katey J. , Gray Douglas A. , Boyd Robert W. , Murugkar Sangeeta , Lo Bryan , Trudel Dominique , Senterman Mary K. , Vanderhyden Barbara C.
Published: April 2023

Ovarian aging heterogeneity is not replicated by VCD treatment
TIL signature genes (150-probes and 120-probes) from Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes
Authors: Hammerl Dora , Massink Maarten P.G. , Smid Marcel , van Deurzen Carolien H.M. , Meijers-Heijboer Hanne E.J. , Waisfisz Quinten , Debets Reno , Martens John W.M.
Published: April 2023

gele lists of TIL signature with annotation (original signature = 152 probes; modified signature =120 probes)
Genes related to T cell evasion from Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes
Authors: Hammerl Dora , Massink Maarten P.G. , Smid Marcel , van Deurzen Carolien H.M. , Meijers-Heijboer Hanne E.J. , Waisfisz Quinten , Debets Reno , Martens John W.M.
Published: April 2023

List of tumor micro-environment Gene-sets that are related to T cell evasion (with annotation)
Figure S5 from Clonality, Antigen Recognition, and Suppression of CD8+ T Cells Differentially Affect Prognosis of Breast Cancer Subtypes
Authors: Hammerl Dora , Massink Maarten P.G. , Smid Marcel , van Deurzen Carolien H.M. , Meijers-Heijboer Hanne E.J. , Waisfisz Quinten , Debets Reno , Martens John W.M.
Published: April 2023

Figure S5. Correlation matrix of gene-sets related to T cell evasion. Numbers represent correlation coefficients (r-values). Negative correlations are shown in blue; positive correlations are visualized in red.
Figure S3 from Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort
Authors: Chen Xiaoji , Chang Ching-Wei , Spoerke Jill M. , Yoh Kathryn E. , Kapoor Vidushi , Baudo Charles , Aimi Junko , Yu Mamie , Liang-Chu May M.Y. , Suttmann Rebecca , Huw Ling-Yuh , Gendreau Steven , Cummings Craig , Lackner Mark R.
Published: April 2023

Comparison of WGS at different sequencing coverage.
Figure S1 from Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort
Authors: Chen Xiaoji , Chang Ching-Wei , Spoerke Jill M. , Yoh Kathryn E. , Kapoor Vidushi , Baudo Charles , Aimi Junko , Yu Mamie , Liang-Chu May M.Y. , Suttmann Rebecca , Huw Ling-Yuh , Gendreau Steven , Cummings Craig , Lackner Mark R.
Published: April 2023

Tumor cell line DNA spike-in.
Supplemental Data from Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer
Authors: Croessmann Sarah , Formisano Luigi , Kinch Lisa N. , Gonzalez-Ericsson Paula I. , Sudhan Dhivya R. , Nagy Rebecca J. , Mathew Aju , Bernicker Eric H. , Cristofanilli Massimo , He Jie , Cutler Richard E. , Lalani Alshad S. , Miller Vincent A. , Lanman Richard B. , Grishin Nick V. , Arteaga Carlos L.
Published: April 2023

Table S1 - HER2 mutations Fig S1 - HER2 co-occur Fig S2 - Long Term Fulv. Fig S3 - L755S CI index Fig S4 - L755S RTprofile Fig S5 - Prot Align Fig S6 - Drug Assays Fig S7 - Quant of Drug Fig S8-11 - immunoblot Fig S12 - L755S mouse Fig S13 - S6 IHC - mouse
Supplementary Data Figure S1-5, Table S2, 5-7 from Organoid Cultures as Preclinical Models of Non–Small Cell Lung Cancer
Authors: Shi Ruoshi , Radulovich Nikolina , Ng Christine , Liu Ni , Notsuda Hirotsugu , Cabanero Michael , Martins-Filho Sebastiao N. , Raghavan Vibha , Li Quan , Mer Arvind Singh , Rosen Joshua C. , Li Ming , Wang Yu-Hui , Tamblyn Laura , Pham Nhu-An , Haibe-Kains Benjamin , Liu Geoffrey , Moghal Nadeem , Tsao Ming-Sound
Published: April 2023

Supplementary Data Figure S1-5, Table S2, 5-7
Tables S2-S9 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
Authors: Courtney Kevin D. , Ma Yuanqing , Diaz de Leon Alberto , Christie Alana , Xie Zhiqun , Woolford Layton , Singla Nirmish , Joyce Allison , Hill Haley , Madhuranthakam Ananth J. , Yuan Qing , Xi Yin , Zhang Yue , Chang Jenny , Fatunde Oluwatomilade , Arriaga Yull , Frankel Arthur E. , Kalva Sanjeeva , Zhang Song , McKenzie Tiffani , Reig Torras Oscar , Figlin Robert A. , Rini Brian I. , McKay Renée M. , Kapur Payal , Wang Tao , Pedrosa Ivan , Brugarolas James
Published: April 2023

Supplementary Tables S2-S9.
Table S1 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
Authors: Courtney Kevin D. , Ma Yuanqing , Diaz de Leon Alberto , Christie Alana , Xie Zhiqun , Woolford Layton , Singla Nirmish , Joyce Allison , Hill Haley , Madhuranthakam Ananth J. , Yuan Qing , Xi Yin , Zhang Yue , Chang Jenny , Fatunde Oluwatomilade , Arriaga Yull , Frankel Arthur E. , Kalva Sanjeeva , Zhang Song , McKenzie Tiffani , Reig Torras Oscar , Figlin Robert A. , Rini Brian I. , McKay Renée M. , Kapur Payal , Wang Tao , Pedrosa Ivan , Brugarolas James
Published: April 2023

Supplementary Table S1. Multiparametric magnetic resonance imaging (mpMRI) acquisition parameters.
Figure S4 from HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
Authors: Courtney Kevin D. , Ma Yuanqing , Diaz de Leon Alberto , Christie Alana , Xie Zhiqun , Woolford Layton , Singla Nirmish , Joyce Allison , Hill Haley , Madhuranthakam Ananth J. , Yuan Qing , Xi Yin , Zhang Yue , Chang Jenny , Fatunde Oluwatomilade , Arriaga Yull , Frankel Arthur E. , Kalva Sanjeeva , Zhang Song , McKenzie Tiffani , Reig Torras Oscar , Figlin Robert A. , Rini Brian I. , McKay Renée M. , Kapur Payal , Wang Tao , Pedrosa Ivan , Brugarolas James
Published: April 2023

Supplementary Figure S4. p53 mutation in Pt27 metastasis progressing on PT2385.
Supplementary experimental procedure from Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non–Small Cell Lung Cancer In Vitro and In Vivo
Authors: Naz Sarwat , Sowers Anastasia , Choudhuri Rajani , Wissler Maria , Gamson Janet , Mathias Askale , Cook John A. , Mitchell James B.
Published: April 2023

experimental methods and all supplementary figure legends
Supplementary Table 1 from Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer
Authors: Seo Yongwoo David , Jiang Xiuyun , Sullivan Kevin M. , Jalikis Florencia G. , Smythe Kimberly S. , Abbasi Arezou , Vignali Marissa , Park James O. , Daniel Sara K. , Pollack Seth M. , Kim Teresa S. , Yeung Raymond , Crispe Ian Nicholas , Pierce Robert H. , Robins Harlan , Pillarisetty Venu G.
Published: April 2023

Patient demographic and tumor pathology
Figure S1 from Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non–Small Cell Lung Cancer In Vitro and In Vivo
Authors: Naz Sarwat , Sowers Anastasia , Choudhuri Rajani , Wissler Maria , Gamson Janet , Mathias Askale , Cook John A. , Mitchell James B.
Published: April 2023

Figure S1. Radiation survival curve of H460 cells treated with Palbociclib (A) Ribociclib (B) and Abemaciclib (C) at a dose of 1µM and 10µM administered either 24 hour pre-or post for indicated dose (Gy) of radiation exposure. (D) Full dose survival curve of H460 cells treated with 10µM of Abemaciclib 24 hr pre-IR exposure.
Supplementary Figure 3 from Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer
Authors: Seo Yongwoo David , Jiang Xiuyun , Sullivan Kevin M. , Jalikis Florencia G. , Smythe Kimberly S. , Abbasi Arezou , Vignali Marissa , Park James O. , Daniel Sara K. , Pollack Seth M. , Kim Teresa S. , Yeung Raymond , Crispe Ian Nicholas , Pierce Robert H. , Robins Harlan , Pillarisetty Venu G.
Published: April 2023

PDA tumor slice culture platform utilized for multimodal analysis before and after ex vivo immune modulation
Supplementary Data from Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group
Authors: Phillips Christine L. , Lane Adam , Gerbing Robert B. , Alonzo Todd A. , Wilkey Alyss , Radloff Gretchen , Lange Beverly , Gamazon Eric R. , Dolan M. Eileen , Davies Stella M.
Published: April 2023

Aim 1: SNPs included in analysis
Supplementary Figure 1 from Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer
Authors: Seo Yongwoo David , Jiang Xiuyun , Sullivan Kevin M. , Jalikis Florencia G. , Smythe Kimberly S. , Abbasi Arezou , Vignali Marissa , Park James O. , Daniel Sara K. , Pollack Seth M. , Kim Teresa S. , Yeung Raymond , Crispe Ian Nicholas , Pierce Robert H. , Robins Harlan , Pillarisetty Venu G.
Published: April 2023

Image cytometry infiltration results by layer
Table S4 from Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics
Authors: Yim John H. , Choi Audrey H. , Li Arthur X. , Qin Hanjun , Chang Sue , Tong Sun-Wing T. , Chu Peiguo , Kim Byung-Wook , Schmolze Daniel , Lew Ryan , Ibrahim Yasmine , Poroyko Valeriy A. , Salvatierra Sylvana , Baker Alysha , Wang Jinhui , Wu Xiwei , Pfeifer Gerd P. , Fong Yuman , Hahn Maria A.
Published: April 2023

DDMS diagnostics for adjacent thyroid tissues. The table contains cancer risk scores according to DDMS, diagnosis according to DDMS and status of nodule to which tissue was adjacent.
Table S1 from Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics
Authors: Yim John H. , Choi Audrey H. , Li Arthur X. , Qin Hanjun , Chang Sue , Tong Sun-Wing T. , Chu Peiguo , Kim Byung-Wook , Schmolze Daniel , Lew Ryan , Ibrahim Yasmine , Poroyko Valeriy A. , Salvatierra Sylvana , Baker Alysha , Wang Jinhui , Wu Xiwei , Pfeifer Gerd P. , Fong Yuman , Hahn Maria A.
Published: April 2023

DDMS diagnostics of thyroid nodules. The table contains post-surgical diagnosis according to participating pathologists, diagnosis based on fine needle aspiration biopsy, presence of thyroiditis and Hurthle cells, cancer risk scores according to DDMS and diagnosis according to DDMS.
Figure S9 from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma
Authors: Lorch Gwendolen , Sivaprakasam Karthigayini , Zismann Victoria , Perdigones Nieves , Contente-Cuomo Tania , Nazareno Alexandra , Facista Salvatore , Wong Shukmei , Drenner Kevin , Liang Winnie S. , Amann Joseph M. , Sinicropi-Yao Sara L. , Koenig Michael J. , La Perle Krista , Whitsett Timothy G. , Murtaza Muhammed , Trent Jeffrey M. , Carbone David P. , Hendricks William P.D.
Published: April 2023

Canine primary lung cancer cell line sensitivity to trastuzumab. Five canine cell lines (three HER2WT and two HER2V659E) and one human cell line BT474 (HER2amp) were treated with 10 trastuzumab doses ranging from 1x10-6 Î¼g/ml to 1000 Î¼g/ml for 72 hours with CellTiterGlo viability endpoints measured and shown as percent growth inhibition relative to PBS vehicle control. Relative survival was measured with respect of the sensitive cell line BT474.
Figure S8 from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma
Authors: Lorch Gwendolen , Sivaprakasam Karthigayini , Zismann Victoria , Perdigones Nieves , Contente-Cuomo Tania , Nazareno Alexandra , Facista Salvatore , Wong Shukmei , Drenner Kevin , Liang Winnie S. , Amann Joseph M. , Sinicropi-Yao Sara L. , Koenig Michael J. , La Perle Krista , Whitsett Timothy G. , Murtaza Muhammed , Trent Jeffrey M. , Carbone David P. , Hendricks William P.D.
Published: April 2023

Canine primary lung cancer cell line sensitivity to erlotinib. Five canine cell lines (three HER2WT and two HER2V659E) and one human cell line BT474 (HER2amp) were treated with 10 erlotinib doses ranging from 5x10-8 to 50 Î¼M for 72 hours with CellTiterGlo viability endpoints measured and shown as percent growth inhibition relative to DMSO vehicle control.
Figure S6 from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma
Authors: Lorch Gwendolen , Sivaprakasam Karthigayini , Zismann Victoria , Perdigones Nieves , Contente-Cuomo Tania , Nazareno Alexandra , Facista Salvatore , Wong Shukmei , Drenner Kevin , Liang Winnie S. , Amann Joseph M. , Sinicropi-Yao Sara L. , Koenig Michael J. , La Perle Krista , Whitsett Timothy G. , Murtaza Muhammed , Trent Jeffrey M. , Carbone David P. , Hendricks William P.D.
Published: April 2023

HER2 cellular location and function in primary canine lung cancer. (A) Canine papillary adenocarcinoma with intense, complete, circumferential membrane (white arrow) and lateral cytoplasmic membrane (black arrow) anti-HER2 antibody positive staining (brown) in a patient with wild-type HER2. (B) Canine papillary adenocarcinoma with moderate cytoplasmic (black arrow) anti-HER2 antibody positive staining (light brown) in a patient with wild-type HER2. x 40; bar 50 Âµm. (C) Anti-HER2 immunohistochemistry of a Grade 1 canine papillary adenocarcinoma wild type for HER2. x 20. (D) Segmentation mark-up of the tumor from adjacent normal lung. Tumor is identified by green, whereas red is area within tumor that contains no tissue, and yellow represents areas of non-tumor such as necrosis or tumor stroma. x20.
Supplementary Data from The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients
Authors: Vozenin Marie-Catherine , De Fornel Pauline , Petersson Kristoffer , Favaudon Vincent , Jaccard Maud , Germond Jean-François , Petit Benoit , Burki Marco , Ferrand Gisèle , Patin David , Bouchaab Hanan , Ozsahin Mahmut , Bochud François , Bailat Claude , Devauchelle Patrick , Bourhis Jean
Published: April 2023

Supplementary Data Table S1: WHO staging system (TNM Classification of Tumors in Domestic Animals. Geneva: World Health Organization; 1980) Table S2: Cat patient and treatment characteristics
Figure S2 from Identification of Recurrent Activating HER2 Mutations in Primary Canine Pulmonary Adenocarcinoma
Authors: Lorch Gwendolen , Sivaprakasam Karthigayini , Zismann Victoria , Perdigones Nieves , Contente-Cuomo Tania , Nazareno Alexandra , Facista Salvatore , Wong Shukmei , Drenner Kevin , Liang Winnie S. , Amann Joseph M. , Sinicropi-Yao Sara L. , Koenig Michael J. , La Perle Krista , Whitsett Timothy G. , Murtaza Muhammed , Trent Jeffrey M. , Carbone David P. , Hendricks William P.D.
Published: April 2023

Somatic copy number plots derived from exome sequencing of five primary canine pulmonary adenocarcinomas (cPAC) and matched constitutional DNA. Tumor copy number states determined by tCoNutT analysis of tumors and matched constitutional DNA from five cPAC cases is shown with each canine chromosome plotted on the x-axis (shown in alternating green and black) and log2 fold change shown on the y-axis.
Supplemental Figure 2 from Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
Authors: Mato Anthony R. , Roeker Lindsey E. , Jacobs Ryan , Hill Brian T. , Lamanna Nicole , Brander Danielle , Shadman Mazyar , Ujjani Chaitra S. , Yazdy Maryam Sarraf , Perini Guilherme Fleury , Pinilla-Ibarz Javier A. , Barrientos Jacqueline , Skarbnik Alan P. , Torka Pallawi , Pu Jeffrey J. , Pagel John M. , Gohil Satyen , Fakhri Bita , Choi Michael , Coombs Catherine C. , Rhodes Joanna , Barr Paul M. , Portell Craig A. , Parry Helen , Garcia Christine A. , Whitaker Kate J. , Winter Allison M. , Sitlinger Andrea , Khajavian Sirin , Grajales-Cruz Ariel F. , Isaac Krista M. , Shah Pratik , Akhtar Othman S. , Pocock Rachael , Lam Kentson , Voorhees Timothy J. , Schuster Stephen J. , Rodgers Thomas D. , Fox Christopher P. , Martinez-Calle Nicolas , Munir Talha , Bhavsar Erica B. , Bailey Neil , Lee Jason C. , Weissbrot Hanna B. , Nabhan Chadi , Goodfriend Julie M. , King Amber C. , Zelenetz Andrew D. , Dorsey Colleen , Bigelow Kayla , Cheson Bruce D. , Allan John N. , Eyre Toby A.
Published: April 2023

Supplemental Figure 2: Progression free survival of patients without prior BTKi exposure who had progressed on venetoclax and were then treated with BTKi.
MHC class I peptidome analysis from Antibody-based Delivery of TNF to the Tumor Neovasculature Potentiates the Therapeutic Activity of a Peptide Anticancer Vaccine
Authors: Probst Philipp , Stringhini Marco , Ritz Danilo , Fugmann Tim , Neri Dario
Published: April 2023

MaxQuant raw output, including peptide sequence and modifications, precursor mass and charge as well as peptide scores and associated statistical information
Supplemental legend from Mast Cell Activation and KSHV Infection in Kaposi Sarcoma
Authors: Ayers Leona W. , Barbachano-Guerrero Arturo , McAllister Shane C. , Ritchie Julie A. , Asiago-Reddy Elizabeth , Bartlett Linda C. , Cesarman Ethel , Wang Dongliang , Rochford Rosemary , Martin Jeffrey N. , King Christine A.
Published: April 2023

Supplemental legend
supplemental methods from D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells
Authors: Zhang Lingjun , Sorensen Mia D. , Kristensen Bjarne W. , Reifenberger Guido , McIntyre Thomas M. , Lin Feng
Published: April 2023

details of methods and materials
Supplementary Data from DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN–WEE1 Signaling
Authors: Li Jie , Pan Chaoyun , Boese Austin C. , Kang JiHoon , Umano Anna D. , Magliocca Kelly R. , Yang Wenqing , Zhang Yu , Lonial Sagar , Jin Lingtao , Kang Sumin
Published: April 2023

Supplementary Fig S2
Table S1 from D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells
Authors: Zhang Lingjun , Sorensen Mia D. , Kristensen Bjarne W. , Reifenberger Guido , McIntyre Thomas M. , Lin Feng
Published: April 2023

Summary of the immunohistochemical staining results
Supplementary Data from DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN–WEE1 Signaling
Authors: Li Jie , Pan Chaoyun , Boese Austin C. , Kang JiHoon , Umano Anna D. , Magliocca Kelly R. , Yang Wenqing , Zhang Yu , Lonial Sagar , Jin Lingtao , Kang Sumin
Published: April 2023

Supplementary Fig S5
Supplementary Data from Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma
Authors: Poty Sophie , Carter Lukas M. , Mandleywala Komal , Membreno Rosemery , Abdel-Atti Dalya , Ragupathi Ashwin , Scholz Wolfgang W. , Zeglis Brian M. , Lewis Jason S.
Published: April 2023

Supplementary Data
Supplementary Data from Exosome-Transmitted PSMA3 and PSMA3-AS1 Promote Proteasome Inhibitor Resistance in Multiple Myeloma
Authors: Xu Hongxia , Han Huiying , Song Sha , Yi Nengjun , Qian Chen'ao , Qiu Yingchun , Zhou Wenqi , Hong Yating , Zhuang Wenyue , Li Zhengyi , Li Bingzong , Zhuang Wenzhuo
Published: April 2023

Supplemental materials and methods, Table S1-S7, Figure S1-5. Supplementary Table 1. Characterization of myeloma patients Supplementary Table 2. Primers used in this study Supplementary Table 3. Sequences of siRNA against specific target in this study Supplementary Table 4, 5. In silico analysis of PSMA3-AS1 coding potential. Supplementary Table 5. Prediction of putative proteins encoded by PSMA3-AS1 using CPAT. 19 Supplementary Table 6. Summary for the results of univariate multivariable analysis. Supplementary Table 7. C-index of ISS alone, ISS with PSMA3, and ISS with PSMA3-AS1 Figure S1. MSCs derived exosomes were transferred to myeloma cells and conferred proteasome inhibitors resistance to myeloma cells. Figure S2. Identifying mRNAs involved in bortezomib-resistant patients. Figure S3. Exosome-mediated transfer of PSMA3 and PSMA3-AS1 from MSCs to MM cells contributed to proteasome inhibitors resistance. Figure S4. PSMA3-AS1 reduced proteasome inhibitors sensitivity by regulating PSMA3 expression in MM cells. Figure S5. PSMA3-AS1 formed an RNA duplex with PSMA3-AS1 pre-mRNA and increased its stability.
Figure S2A from Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study
Authors: Dillon Magnus T. , Grove Lorna , Newbold Kate L. , Shaw Heather , Brown Nicholas F. , Mendell Jeanne , Chen Shuquan , Beckman Robert A. , Jennings Anne , Ricamara Marivic , Greenberg Jonathan , Forster Martin , Harrington Kevin J.
Published: April 2023

Figure S2A
Supplementary Figure S5 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Figure S5
Supplementary Figure S2 from Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors
Authors: Gebreyohannes Yemarshet K. , Wozniak Agnieszka , Zhai Madalina-Elena , Wellens Jasmien , Cornillie Jasmien , Vanleeuw Ulla , Evans Erica , Gardino Alexandra K. , Lengauer Christoph , Debiec-Rychter Maria , Sciot Raf , Schöffski Patrick
Published: April 2023

Mouse body weight during the course of treatment is presented as percent of the baseline value in the three xenografts.
Supplementary Data from DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway
Authors: Adam Liana , San Lucas F. Anthony , Fowler Richard , Yu Yao , Wu Wenhui , Liu Yulun , Wang Huamin , Menter David , Tetzlaff Michael T. , Ensor Joe , Manyam Ganiraju , Arold Stefan T. , Huff Chad , Kopetz Scott , Scheet Paul , Overman Michael J.
Published: April 2023

Supplemental Figure 1
Supplementary Figure S18 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Figure S18
Supplementary Data from DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway
Authors: Adam Liana , San Lucas F. Anthony , Fowler Richard , Yu Yao , Wu Wenhui , Liu Yulun , Wang Huamin , Menter David , Tetzlaff Michael T. , Ensor Joe , Manyam Ganiraju , Arold Stefan T. , Huff Chad , Kopetz Scott , Scheet Paul , Overman Michael J.
Published: April 2023

Supplemental Figure 3
Supplementary Figure S16 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Figure S16
Supplementary Data from DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway
Authors: Adam Liana , San Lucas F. Anthony , Fowler Richard , Yu Yao , Wu Wenhui , Liu Yulun , Wang Huamin , Menter David , Tetzlaff Michael T. , Ensor Joe , Manyam Ganiraju , Arold Stefan T. , Huff Chad , Kopetz Scott , Scheet Paul , Overman Michael J.
Published: April 2023

Table S4
Supplementary Figures from Tumor Subtype Determines Therapeutic Response to Chimeric Polypeptide Nanoparticle–based Chemotherapy in Pten-deleted Mouse Models of Sarcoma
Authors: Dodd Rebecca D. , Scherer Amanda , Huang Wesley , McGivney Gavin R. , Gutierrez Wade R. , Laverty Emily A. , Ashcraft Kathleen A. , Stephens Victoria R. , Yousefpour Parisa , Saha Soumen , Knepper-Adrian Vickie , Floyd Warren , Chen Mark , Ma Yan , Mastria Eric M. , Cardona Diana M. , Eward William C. , Chilkoti Ashutosh , Kirsch David G.
Published: April 2023

Supplementary Figures
Supplementary Figure S12 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Figure S12
Supplementary Figure S11 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Figure S11
Supplementary eTables from Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Authors: Tanioka Maki , Fan Cheng , Parker Joel S. , Hoadley Katherine A. , Hu Zhiyuan , Li Yan , Hyslop Terry M. , Pitcher Brandelyn N. , Soloway Matthew G. , Spears Patricia A. , Henry Lynn N. , Tolaney Sara , Dang Chau T. , Krop Ian E. , Harris Lyndsay N. , Berry Donald A. , Mardis Elaine R. , Winer Eric P. , Hudis Clifford A. , Carey Lisa A. , Perou Charles M.
Published: April 2023

Supplementary eTables 1-12
Supplementary Figure S1 from A CpG Methylation Classifier to Predict Relapse in Adults with T-Cell Lymphoblastic Lymphoma
Authors: Tian Xiao-Peng , Su Ning , Wang Liang , Huang Wei-Juan , Liu Yan-Hui , Zhang Xi , Huang Hui-Qiang , Lin Tong-Yu , Ma Shu-Yun , Rao Hui-Lan , Li Mei , Liu Fang , Zhang Fen , Zhong Li-Ye , Liang Li , Lan Xiao-Liang , Li Juan , Liao Bing , Li Zhi-Hua , Tang Qiong-Lan , Liang Qiong , Shao Chun-Kui , Zhai Qiong-Li , Cheng Run-Fen , Sun Qi , Ru Kun , Gu Xia , Lin Xi-Na , Yi Kun , Shuang Yue-Rong , Chen Xiao-Dong , Dong Wei , Sun Cai , Sang Wei , Liu Hui , Zhu Zhi-Gang , Rao Jun , Guo Qiao-Nan , Zhou Ying , Meng Xiang-Ling , Zhu Yong , Hu Chang-Lu , Jiang Yi-Rong , Zhang Ying , Gao Hong-Yi , He Wen-Jun , Xia Zhong-Jun , Pan Xue-Yi , Hai Lan , Li Guo-Wei , Song Li-Yan , Kang Tie-Bang , Xie Dan , Cai Qing-Qing
Published: April 2023

Supplementary Figure S1
Supplementary Figures from Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer
Authors: Tanioka Maki , Fan Cheng , Parker Joel S. , Hoadley Katherine A. , Hu Zhiyuan , Li Yan , Hyslop Terry M. , Pitcher Brandelyn N. , Soloway Matthew G. , Spears Patricia A. , Henry Lynn N. , Tolaney Sara , Dang Chau T. , Krop Ian E. , Harris Lyndsay N. , Berry Donald A. , Mardis Elaine R. , Winer Eric P. , Hudis Clifford A. , Carey Lisa A. , Perou Charles M.
Published: April 2023

Supplementary Figures 1-5
Tables S1-4 from A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer
Authors: Ponath Paul , Menezes Daniel , Pan Chin , Chen Bing , Oyasu Miho , Strachan Debbie , LeBlanc Heidi , Sun Huadong , Wang Xi-Tao , Rangan Vangipuram S. , Deshpande Shrikant , Cristea Sandra , Park Kwon-Sik , Sage Julien , Cardarelli Pina M.
Published: April 2023

4 suppl tables on FucGM1 expression in lung cancer, binding, and mouse PK
Supplemental Methods from 21-Gene Recurrence Score Assay Predicts Benefit of Post-Mastectomy Radiotherapy in T1-2 N1 Breast Cancer
Authors: Goodman Chelain R. , Seagle Brandon-Luke L. , Kocherginsky Masha , Donnelly Eric D. , Shahabi Shohreh , Strauss Jonathan B.
Published: April 2023

Supplemental Methods further defining Variable Selection and Matched Cohort Creation.
Table S2 from Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework
Authors: Netterberg Ida , Karlsson Mats O. , Terstappen Leon W.M.M. , Koopman Miriam , Punt Cornelis J.A. , Friberg Lena E.
Published: April 2023

Î"OFV for the explored drop-out predictors in the first step
Table S7 from The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Authors: Linxweiler Maximilian , Kuo Fengshen , Katabi Nora , Lee Mark , Nadeem Zaineb , Dalin Martin G. , Makarov Vladimir , Chowell Diego , Dogan Snjezana , Ganly Ian , Hakimi A. Ari , Wong Richard J. , Riaz Nadeem , Ho Alan L. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Table S7
Figure S6 from Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework
Authors: Netterberg Ida , Karlsson Mats O. , Terstappen Leon W.M.M. , Koopman Miriam , Punt Cornelis J.A. , Friberg Lena E.
Published: April 2023

KMMC VPCs of the base (top plots) and final (bottom plots) OS model. The observed mean BTS and age (black lines), in comparison to the 95% CI based on 100 simulations from the base and final models (shaded areas), of patients remaining in the study over time are illustrated in the left and right plots, respectively. Vertical lines indicate censored events.
Figure S4 from Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework
Authors: Netterberg Ida , Karlsson Mats O. , Terstappen Leon W.M.M. , Koopman Miriam , Punt Cornelis J.A. , Friberg Lena E.
Published: April 2023

VPC of the tumor size model taking dropout into account. The solid and dashed lines in the left panel represent the observed median and 5th (lower line) and 95th (upper line) percentiles of the data, respectively. The shaded areas in the left panel are the corresponding 95% CIs of the simulated data, derived from 200 simulations from the final tumor size model. The grey horizontal line represents and SLD of 10 mm.
Figure S3 from Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework
Authors: Netterberg Ida , Karlsson Mats O. , Terstappen Leon W.M.M. , Koopman Miriam , Punt Cornelis J.A. , Friberg Lena E.
Published: April 2023

Individual tumor size predictions in the final tumor size model (lines) and observed tumor sizes (dots) for 9 example patients (indicated by the shape of the dots), 3 in each subpopulation.
Table S2 from The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Authors: Linxweiler Maximilian , Kuo Fengshen , Katabi Nora , Lee Mark , Nadeem Zaineb , Dalin Martin G. , Makarov Vladimir , Chowell Diego , Dogan Snjezana , Ganly Ian , Hakimi A. Ari , Wong Richard J. , Riaz Nadeem , Ho Alan L. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Table S2
Table S10 from The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Authors: Linxweiler Maximilian , Kuo Fengshen , Katabi Nora , Lee Mark , Nadeem Zaineb , Dalin Martin G. , Makarov Vladimir , Chowell Diego , Dogan Snjezana , Ganly Ian , Hakimi A. Ari , Wong Richard J. , Riaz Nadeem , Ho Alan L. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Table S10
Supplementary Table S1 from Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma
Authors: Lee Ju Youn , Schizas Michail , Geyer Felipe C. , Selenica Pier , Piscuoglio Salvatore , Sakr Rita A. , Ng Charlotte K.Y. , Carniello Jose V. Scarpa , Towers Russell , Giri Dilip D. , de Andrade Victor P. , Papanastasiou Anastasios D. , Viale Agnes , Harris Reuben S. , Solit David B. , Weigelt Britta , Reis-Filho Jorge S. , King Tari A.
Published: April 2023

Supplementary Table S1: Sequencing statistics.
Figure S8 from The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Authors: Linxweiler Maximilian , Kuo Fengshen , Katabi Nora , Lee Mark , Nadeem Zaineb , Dalin Martin G. , Makarov Vladimir , Chowell Diego , Dogan Snjezana , Ganly Ian , Hakimi A. Ari , Wong Richard J. , Riaz Nadeem , Ho Alan L. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Figure S8
Supplementary Figure S4 from Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma
Authors: Lee Ju Youn , Schizas Michail , Geyer Felipe C. , Selenica Pier , Piscuoglio Salvatore , Sakr Rita A. , Ng Charlotte K.Y. , Carniello Jose V. Scarpa , Towers Russell , Giri Dilip D. , de Andrade Victor P. , Papanastasiou Anastasios D. , Viale Agnes , Harris Reuben S. , Solit David B. , Weigelt Britta , Reis-Filho Jorge S. , King Tari A.
Published: April 2023

Supplementary Fig. S4: Clonal relatedness between lobular carcinoma in situ (LCIS), invasive lobular carcinoma (ILC), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC), Shannon and Gini-Simpson Indices measure of intra-lesion genetic heterogeneity, and truncal and branch mutations affecting cancer genes. A) Pairwise comparison of the clonality index between samples based on the presence of synonymous and non-synonymous somatic mutations. The color gradient represents the CI (Clonal Index) of the probability that a given pair of samples is clonally-related based on the number of shared mutations and the frequency of each shared mutation in ILCs breast cancers from The Cancer Genome Atlas breast cancer study (31). B) Barplot showing the proportion of LCIS harboring intra-lesion genetic heterogeneity in the LCIS clonally-related to DCIS/ILC (red bar) and LCIS not clonally-related to DCIS/ILC (gray bar) (p-value = 0.0016, Fisher's exact test). Boxplots illustrating the distribution of the Shannon diversity index (C) and the Gini-Simpson diversity index (D) for each lesion type (LCIS, DICS, ILC and IDC). E-F) Truncal and branch mutations affecting cancer genes as defined by Kandoth et al. (24), the Cancer Gene Census (25) and/ or Lawrence et al. (26). Venn diagrams representing the overlap between genes affected by truncal or branch mutations and cancer genes. Hypergeometric test P-value and representation factors are shown below the respective Venn diagrams.
Supplementary Figure S3 from Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma
Authors: Lee Ju Youn , Schizas Michail , Geyer Felipe C. , Selenica Pier , Piscuoglio Salvatore , Sakr Rita A. , Ng Charlotte K.Y. , Carniello Jose V. Scarpa , Towers Russell , Giri Dilip D. , de Andrade Victor P. , Papanastasiou Anastasios D. , Viale Agnes , Harris Reuben S. , Solit David B. , Weigelt Britta , Reis-Filho Jorge S. , King Tari A.
Published: April 2023

Supplementary Fig. S3: Repertoire of somatic mutations, clonal composition and phylogenetic tree analysis of cases 19-24.
Supplementary Data File 1 from Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma
Authors: Lee Ju Youn , Schizas Michail , Geyer Felipe C. , Selenica Pier , Piscuoglio Salvatore , Sakr Rita A. , Ng Charlotte K.Y. , Carniello Jose V. Scarpa , Towers Russell , Giri Dilip D. , de Andrade Victor P. , Papanastasiou Anastasios D. , Viale Agnes , Harris Reuben S. , Solit David B. , Weigelt Britta , Reis-Filho Jorge S. , King Tari A.
Published: April 2023

Excel file containing Supplementary Data File 1: Non-synonymous somatic mutations identified by whole-exome sequencing and amplicon sequencing in the LCIS, DCIS, ILCs and IDCs studied.
Figure S3 from The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Authors: Linxweiler Maximilian , Kuo Fengshen , Katabi Nora , Lee Mark , Nadeem Zaineb , Dalin Martin G. , Makarov Vladimir , Chowell Diego , Dogan Snjezana , Ganly Ian , Hakimi A. Ari , Wong Richard J. , Riaz Nadeem , Ho Alan L. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Figure S3
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
Authors: Jaeger Alex M. , Stopfer Lauren , Lee Sunmin , Gaglia Giorgio , Sandel Demi , Santagata Sandro , Lin Nancy U. , Trepel Jane B. , White Forest , Jacks Tyler , Lindquist Susan , Whitesell Luke
Published: April 2023

Clinical Data HSP90 Codeset
Figure S11 from The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Authors: Linxweiler Maximilian , Kuo Fengshen , Katabi Nora , Lee Mark , Nadeem Zaineb , Dalin Martin G. , Makarov Vladimir , Chowell Diego , Dogan Snjezana , Ganly Ian , Hakimi A. Ari , Wong Richard J. , Riaz Nadeem , Ho Alan L. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Figure S11
Figure S10 from The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype
Authors: Linxweiler Maximilian , Kuo Fengshen , Katabi Nora , Lee Mark , Nadeem Zaineb , Dalin Martin G. , Makarov Vladimir , Chowell Diego , Dogan Snjezana , Ganly Ian , Hakimi A. Ari , Wong Richard J. , Riaz Nadeem , Ho Alan L. , Chan Timothy A. , Morris Luc G.T.
Published: April 2023

Figure S10
Supplementary Table 2 from Cancer-Stimulated CAFs Enhance Monocyte Differentiation and Protumoral TAM Activation via IL6 and GM-CSF Secretion
Authors: Cho Haaglim , Seo Youngha , Loke Kin Man , Kim Seon-Wook , Oh Seong-Min , Kim Jun-Hyeong , Soh Jihee , Kim Hyoen Sik , Lee Hyunju , Kim Jin , Min Jung-Joon , Jung Da-Woon , Williams Darren Reece
Published: April 2023

Antibodies used in this study
Supplementary Data from Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation
Authors: Jaeger Alex M. , Stopfer Lauren , Lee Sunmin , Gaglia Giorgio , Sandel Demi , Santagata Sandro , Lin Nancy U. , Trepel Jane B. , White Forest , Jacks Tyler , Lindquist Susan , Whitesell Luke
Published: April 2023

PBMC RNAseq Raw Transcript Counts
Supplementary Data from Shortened Leukocyte Telomere Length Associates with an Increased Prevalence of Chronic Health Conditions among Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort
Authors: Song Nan , Li Zhenghong , Qin Na , Howell Carrie R. , Wilson Carmen L. , Easton John , Mulder Heather L. , Edmonson Michael N. , Rusch Michael C. , Zhang Jinghui , Hudson Melissa M. , Yasui Yutaka , Robison Leslie L. , Ness Kirsten K. , Wang Zhaoming
Published: April 2023

Supplementary Fig. S1-S3, Supplementary Table S1-S9 Supplementary Fig. S1. A flow diagram of the study population. Supplementary Fig. S2. Dynamics of telomere length differs between individuals with no history of cancer and survivors of childhood cancer due to exposures to chemotherapy and/or radiation treatment. Supplementary Fig. S3. Theoretical framework of relationships among telomere length, health behaviors and chronic health conditions.
Supplementary Table S3 from Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
Authors: Serrano César , Leal Alessandro , Kuang Yanan , Morgan Jeffrey A. , Barysauskas Constance M. , Phallen Jillian , Triplett Olivia , Mariño-Enríquez Adrián , Wagner Andrew J. , Demetri George D. , Velculescu Victor E. , Paweletz Cloud P. , Fletcher Jonathan A. , George Suzanne
Published: April 2023

Genes analyzed by TEC-seq.
Table S1 from Analysis of Mucosal Melanoma Whole-Genome Landscapes Reveals Clinically Relevant Genomic Aberrations
Authors: Zhou Rong , Shi Chaoji , Tao Wenjie , Li Jiang , Wu Jing , Han Yong , Yang Guizhu , Gu Ziyue , Xu Shengming , Wang Yujue , Wang Lizhen , Wang Yanan , Zhou Guoyu , Zhang Chenping , Zhang Zhiyuan , Sun Shuyang
Published: April 2023

Whole Genome Sequencing metrics and clinical data of MMs.
Supplementary Methods from Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors
Authors: Serrano César , Leal Alessandro , Kuang Yanan , Morgan Jeffrey A. , Barysauskas Constance M. , Phallen Jillian , Triplett Olivia , Mariño-Enríquez Adrián , Wagner Andrew J. , Demetri George D. , Velculescu Victor E. , Paweletz Cloud P. , Fletcher Jonathan A. , George Suzanne
Published: April 2023

Supplementary methods
Supplementary Data from T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities
Authors: Vardi Anna , Vlachonikola Elisavet , Papazoglou Despoina , Psomopoulos Fotis , Kotta Kostantia , Ioannou Nikolaos , Galigalidou Chrysi , Gemenetzi Katerina , Pasentsis Kostantinos , Kotouza Maria , Koravou Evdoxia , Scarfó Lydia , Iskas Michail , Stavroyianni Niki , Ghia Paolo , Anagnostopoulos Achilles , Kouvatsi Anastasia , Ramsay Alan G. , Stamatopoulos Kostas , Chatzidimitriou Anastasia
Published: April 2023

Supplementary Data
Supplemental legend from A Method to Summarize Toxicity in Cancer Randomized Clinical Trials
Authors: Carbini Mariana , Suárez-Fariñas Mayte , Maki Robert G.
Published: April 2023

Supplemental legend
Supplementary Figure 2 from Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers
Authors: Pozdeyev Nikita , Gay Laurie M. , Sokol Ethan S. , Hartmaier Ryan , Deaver Kelsi E. , Davis Stephanie , French Jena D. , Borre Pierre Vanden , LaBarbera Daniel V. , Tan Aik-Choon , Schweppe Rebecca E. , Fishbein Lauren , Ross Jeffrey S. , Haugen Bryan R. , Bowles Daniel W.
Published: April 2023

Genetic alterations in papillary thyroid cancer
Supplementary Figures from Identification of Deleterious NOTCH Mutation as Novel Predictor to Efficacious Immunotherapy in NSCLC
Authors: Zhang Kai , Hong Xiaohua , Song Zhengbo , Xu Yu , Li Chengcheng , Wang Guoqiang , Zhang Yuzi , Zhao Xiaochen , Zhao Zhengyi , Zhao Jing , Huang Mengli , Huang Depei , Qi Chuang , Gao Chan , Cai Shangli , Gu Feifei , Hu Yue , Xu Chunwei , Wang Wenxian , Lou Zhenkun , Zhang Yong , Liu Li
Published: April 2023

Supplementary Figure S1-S12